EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

Qinyi Cai, Jiayi Xiao, Chenxiang Weng, Huiling Chen

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06643-0 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Qinyi Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Higher Education Innovation Fund project of Gansu Province, Cuiying Scientific and Technological Innovation Program of The Second Hospital & Clinical Medical School, Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This meta-analysis aimed to evaluate the efficacy and safety of venetoclax plus azacitidine (VEN + AZA) regimens in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and to explore the effects of different combination strategies, including chemotherapy and targeted agents, on clinical outcomes. A systematic search of PubMed, Web of Science, Embase, and Cochrane Library databases was performed up to February 2025. Studies that reported complete remission or complete remission with incomplete hematologic recovery (CR/CRi) were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) for Non-Randomized Controlled Trials (NRCTs). Pooled estimates were calculated using random-effects models, and subgroup analyses were performed. The CR/CRi rate for VEN + AZA-based regimens was 43% (95% CI: 33-53%), with substantial heterogeneity (I²=89.20%). Subgroup analysis indicated higher CR/CRi rates for VEN + AZA combined with chemotherapy (68%, 95% CI: 62-73%) compared to VEN + AZA alone (38%, 95% CI: 28-47%) or VEN + AZA with targeted agents (28%, 95% CI: 18-40%). The most common grade ≥ 3 adverse events were neutropenia (89%) and thrombocytopenia (82%). VEN + AZA combined with chemotherapy significantly improved CR/CRi rates in R/R AML compared to VEN + AZA alone or with targeted agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsAzacitidineHumansTreatment OutcomeRecurrence

Stichwörter der Autor:innen

Acute myeloid leukemiaAzacitidineMeta-analysisRefractoryRelapsedVenetoclax

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicAzacitidine

Autor:innen und Institutionen

  • The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
  • The First Hospital and Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
  • The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. chenhuiling618@163.com.

Förderung

  • Higher Education Innovation Fund project of Gansu Province
  • Cuiying Scientific and Technological Innovation Program of The Second Hospital & Clinical Medical School, Lanzhou University

Zitieren

APA

Cai, Q., Xiao, J., Weng, C., & Chen, H. (2025). Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. Annals of Hematology. https://doi.org/10.1007/s00277-025-06643-0

Vancouver

Cai Q, Xiao J, Weng C, Chen H. Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. Annals of Hematology. 2025. doi:10.1007/s00277-025-06643-0

BibTeX
@article{Cai2025,
  author = {Cai, Qinyi and Xiao, Jiayi and Weng, Chenxiang and Chen, Huiling},
  title = {Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06643-0}
}
Kostenlos starten →